Published in J Neuropathol Exp Neurol on October 01, 2006
Advancing translational research with the Semantic Web. BMC Bioinformatics (2007) 4.38
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci (2007) 1.59
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta (2008) 1.55
Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord (2007) 1.44
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) (2011) 1.35
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation (2008) 1.18
Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J Neuropathol Exp Neurol (2009) 1.11
LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One (2012) 1.10
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol (2007) 1.08
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 1.05
Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J Neuropathol Exp Neurol (2009) 1.03
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging (2008) 1.03
Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front Mol Neurosci (2014) 1.03
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener (2006) 1.00
Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegener (2009) 0.98
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS One (2013) 0.93
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J Neural Transm (Vienna) (2009) 0.93
Effects of mitochondrial dysfunction on the immunological properties of microglia. J Neuroinflammation (2010) 0.92
LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum Mol Genet (2012) 0.89
Update on the functional biology of Lrrk2. Future Neurol (2008) 0.89
Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One (2013) 0.88
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design. Future Med Chem (2012) 0.86
Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. Biomed Res Int (2014) 0.86
Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys. Exp Neurol (2010) 0.85
Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener Dis (2008) 0.84
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? Brain Res (2014) 0.80
Anti-inflammatory treatment induced regenerative oligodendrogenesis in parkinsonian mice. Stem Cell Res Ther (2012) 0.78
Bacterial Amyloid and DNA are Important Constituents of Senile Plaques: Further Evidence of the Spirochetal and Biofilm Nature of Senile Plaques. J Alzheimers Dis (2016) 0.78
Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease. J Neuroinflammation (2015) 0.77
Parkinson's disease: leucine-rich repeat kinase 2 and autophagy, intimate enemies. Parkinsons Dis (2012) 0.75
Synthesis and In Vitro and In Vivo Evaluation of [(3)H]LRRK2-IN-1 as a Novel Radioligand for LRRK2. Mol Imaging Biol (2017) 0.75
The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology (2008) 3.64
Draft genome sequence of chickpea (Cicer arietinum) provides a resource for trait improvement. Nat Biotechnol (2013) 3.41
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
Glial reactions in Parkinson's disease. Mov Disord (2008) 2.62
NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging (2006) 2.55
Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 2.41
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain (2007) 2.25
Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet (2009) 2.23
Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci (2004) 2.11
Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.04
Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett (2008) 1.76
Inflammation, the complement system and the diseases of aging. Neurobiol Aging (2005) 1.70
Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis (2010) 1.68
PrP conformational transitions alter species preference of a PrP-specific antibody. J Biol Chem (2010) 1.62
Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol (2002) 1.59
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis (2006) 1.58
Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol (2008) 1.56
Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep (2013) 1.49
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.41
Severe vascular disturbance in a case of familial brain calcinosis. Acta Neuropathol (2005) 1.38
Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol (2007) 1.38
Genome sequencing of the high oil crop sesame provides insight into oil biosynthesis. Genome Biol (2014) 1.38
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology (2004) 1.29
Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia (2007) 1.26
Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis (2008) 1.24
Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging (2006) 1.24
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol (2013) 1.23
Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem (2011) 1.22
Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS Lett (2008) 1.21
Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res (2002) 1.21
Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem (2010) 1.20
The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. EMBO Mol Med (2009) 1.20
Astrocytes are GABAergic cells that modulate microglial activity. Glia (2011) 1.19
Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J (2010) 1.18
Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation (2008) 1.18
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol (2004) 1.18
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett (2009) 1.17
Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J (2006) 1.17
Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol (2008) 1.15
Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging (2009) 1.14
Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol (2011) 1.14
Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. BMC Cancer (2014) 1.13
Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS Lett (2007) 1.12
Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol (2007) 1.11
Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol (2003) 1.10
Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun (2009) 1.09
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol (2006) 1.09
Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol (2010) 1.07
Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging (2002) 1.06
Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs (2005) 1.05
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging (2008) 1.03
Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta (2009) 1.01
Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res (2005) 1.01
Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem (2004) 1.00
Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia (2010) 0.99
Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med (2004) 0.98
Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One (2012) 0.98
A near-infrared-fluorescent chemodosimeter for mercuric ion based on an expanded porphyrin. Angew Chem Int Ed Engl (2006) 0.97
Mechanisms of GABA release from human astrocytes. Glia (2011) 0.96
Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia (2003) 0.96
A convenient route to silyl linked bis(amidinate) ligands and synthesis of group(I) metal derivatives. Dalton Trans (2006) 0.96
Targeting microglia for the treatment of Alzheimer's disease. Expert Opin Ther Targets (2014) 0.94
Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging (2008) 0.93
History of innate immunity in neurodegenerative disorders. Front Pharmacol (2011) 0.93
TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. Acta Neuropathol (2009) 0.92
N-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease. J Biol Chem (2010) 0.92
Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren's syndrome. Rheumatology (Oxford) (2011) 0.92
Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol (2008) 0.91
Clinicopathological characterization of Pick's disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions. Acta Neuropathol (2009) 0.91
Nonenzymatic hydrogen peroxide electrochemical sensor based on carbon-coated SnO2 supported Pt nanoparticles. Colloids Surf B Biointerfaces (2012) 0.90
The possible role of complement activation in Alzheimer disease. Trends Mol Med (2002) 0.90
Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neurosci Lett (2002) 0.89
Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain (2012) 0.89